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Summary
Objective: To determine whether glucosamine inhibits experimentally induced degradation of equine articular cartilage explants.
Methods: Articular cartilage was obtained from the antebrachio-carpal and middle joints of horses (2–8 years old) killed for reasons unrelated
to lameness. Cartilage discs were harvested from the weight-bearing region of the articular surface and cultured. Media were exchanged
daily and the recovered media stored at 4°C. Explants were maintained in basal media 2 days prior to the start of four treatment days. On
days 1–4 lipopolysaccharide (LPS, 10 g/ml) or recombinant human interleukin-1 (rhIL-1, 50 ng/ml) were added to induce cartilage
degradation. To test the potential protective effects of glucosamine, the compound was added in three concentrations (0.25, 2.5, or 25 mg/ml)
and treatments were performed in triplicate. Controls included wells without LPS, rhIL-1, or glucosamine. Nitric oxide, proteoglycan and
matrix metalloproteinases (MMP) released into conditioned media and tissue proteoglycan synthesis were measured as indicators of
cartilage metabolism.
Results: Maximal nitric oxide production, proteoglycan release, and MMP activity were detected 1 day after the addition of LPS or rhIL-1
to the media. The addition of 25 mg/ml of glucosamine prevented the increase in nitric oxide production, proteoglycan release and MMP
activity induced by LPS or rhIL-1.
Conclusions: These data indicate that glucosamine can prevent experimentally induced cartilage degradation in vitro. © 2000 OsteoArthritis
Research Society International
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In elderly humans, osteoarthritis (OA) is the primary lower
extremity disease1 with an estimated annual cost in the US
alone of $15.5 billion.2 The symptoms of OA are also a
principal cause of lameness and decreased performance in
horses. OA is characterized by progressive and permanent
degeneration of articular cartilage and commonly develops
in previously normal joints that are damaged by a variety of
factors. These factors can include developmental dis-
orders,3 sudden4 and repetitive injury to a joint or cartilage
surface,5,6 joint infections, and/or medications that alter
cartilage integrity.
OA is the result of an imbalance in normal cartilage
extracellular matrix turnover with degradation exceeding
synthesis.7,8 Increased proteolytic enzyme activity is a
major factor responsible for matrix degradation.9,10 Specific
changes include a decreased proteoglycan (PG) content,11
changes in PG structure,12 and increased water con-
tent.13,14 In addition, collagen fibers become fragmented.15
This degradation of articular cartilage results in decreased
compressive and tensile stiffness.16258Initially, in diseased cartilage, matrix synthesis increases
in an attempt to compensate for increased degradation.17
However, as the disease progresses, matrix synthesis
eventually decreases. Interleukin-1 (IL-1), a cytokine
present in elevated amounts in OA cartilage and synovial
fluid, is an important mediator of increased matrix degra-
dation and reduced PG synthesis.18 IL-1 mediates this
process by a number of processes including up-regulating
enzymes such as inducible nitric oxide synthase,19 and
matrix metalloproteinases (MMPs). Enhanced production
of nitric oxide (NO) by chondrocytes20 depresses the
synthesis of PGs21 and may activate MMPs.22 Equine
chondrocytes have recently been shown to produce nitric
oxide in response to two arthritogenic molecules, lipopoly-
saccharide (LPS) or recombinant interleukin-1 (rhIL-1).23
Oral supplements that prevent cartilage degradation
and/or joint injury are an attractive solution for the treatment
of OA in humans and domestic animals. Glucosamine is a
potential anti-arthritic compound currently being marketed.
It is a naturally occurring, nontoxic compound that when
given orally has been shown to decrease pain and improve
mobility in osteoarthritic joints in a number of studies in
humans.24 In addition, drug tolerance to glucosamine sul-
fate was similar when control groups were given either
ibuprofen25,26 or a lactose placebo.27 One difference
between ibuprofen and glucosamine sulfate treatment was
that ibuprofen alleviated pain after only 2 weeks compared
to 4 weeks for glucosamine sulfate. However, the ibuprofen
treated group experienced renewed symptoms during the
trial period.25 Controlled clinical studies of the efficacy ofReceived 15 July 1999; accepted 1 December 1999.
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Osteoarthritis and Cartilage Vol. 8 No. 4 259glucosamine in horses are lacking. However, in horses
suffering from clinical signs of OA, an orally administered
glucosamine-chondroitin sulfate compound rapidly allevi-
ated OA symptoms.28 The majority of clinical studies in
humans and horses have evaluated the ability of glu-
cosamine to relieve pain but have not evaluated its ability to
inhibit cartilage degradation. Admittedly this is difficult to
accomplish in vivo.
In vitro, glucosamine has been shown to have favorable
effects on chondrocytes isolated from adult articular carti-
lage, including a reduction in extracellular matrix break-
down and stimulation of synthesis of matrix components
by chondrocytes,29 potentially alleviating the imbalance
between synthesis and degradation characteristic of OA.
Recently, glucosamine was shown to inhibit aggrecanase
(a member of the ADAMTS family) activity in vitro.30
Largely anecdotal support for clinical efficacy of glucosa-
mine, paralleled by limited biochemical studies, suggest a
need for further study of the effects of this molecule. In the
present study, we tested whether glucosamine inhibits
experimentally induced cartilage degradation as indicated
by NO production, PG release, MMP activity, and PG
synthesis in equine articular cartilage explants. We report
that glucosamine inhibits the release of these indicators of
cartilage degradation. Our results support the hypothesis
that glucosamine has the potential to prevent or reduce
articular cartilage degradation.
Materials and methods
All chemicals, including glucosamine HCl and glucose,
were purchased from Sigma (St Louis, MO, U.S.A.) unless
otherwise noted.
EXPLANT CULTURES
Articular cartilage was obtained from the antebrachio-
carpal and middle carpal joints of horses (2–8 years old)
killed for reasons other than joint problems. Cartilage discs
(3.5 mm) were biopsied from the weight-bearing region of
the articular surface. Randomly selected explant discs (3
per well, approximately 40 mg total) were cultured in a
24-well Falcon culture plate (Fisher Scientific, Pittsburgh,
PA) with a modified version of Dulbecco’s modified Eagle’s
medium: nutrient mixture F-12 (Ham) (1:1) (Gibco, Grand
Island, NY).31 The media was supplemented with 10% fetal
bovine serum (FBS, Gibco), 50 g/ml ascorbate and 100
units/ml penicillin/streptomycin (Gibco). The explants were
maintained in culture in a humidified incubator with 7% CO2
at 37°C.
Explants were maintained in media without serum for 2
days prior to the first of four treatment days. Conditioned
media were removed and replaced daily and stored at 4°C
until analysed for indicators of degradation. LPS (10 g/ml)
or rhIL-1 (50 ng/ml) (R&D Systems Inc; Minneapolis, MN,
U.S.A.) was added to induce cartilage degradation. To
evaluate the effects of glucosamine, varying concentrations
of glucosamine HCl (0.25, 2.5, or 25 mg/ml) or glucose
control (0.21, 2.1 or 21.0 mg/ml; equimolar basis to glu-
cosamine) were added to the cultures. Each experiment
contained a control in which neither IL-1 nor LPS was
added to the media (FBS). Treatments were performed with
triplicate wells using tissue from one animal donor. Exper-
iments were repeated at least five times, each time using
tissue from a different animal donor.LACTATE DEHYDROGENASE ASSAY
Lactate dehydrogenase activity in the conditioned media
was measured using a commercial cytotoxicity detection kit
(Boehringer Mannheim, Indianapolis, IN). Lactate dehydro-
genase was measured as an indicator of chondrocyte
viability during culture.32
PROTEOGLYCAN ASSAY
PG release into conditioned media was measured using
a dimethylmethylene blue assay as previously described.33
Briefly, PG content was determined by measuring sulfated
glycosaminoglycan content compared to a chondroitin sul-
fate standard and expressed as g PG/well since each well
contained similar amounts of cartilage. Tissue PG content
was determined following papain digest (1 g papain/mg
tissue) of the tissue.34 Tissue PG content was expressed
as g PG/mg tissue wet weight.
NITRIC OXIDE ASSAY
Nitrite, a stable end product of nitric oxide metabolism,
was measured in conditioned media using the Greiss
reaction and sodium nitrite as a standard.35 Absorbance at
540 nm was determined using the SpectraMax 300 plate
reader (Molecular Devices, Sunnyvale, CA). Results are
expressed as M of NO/well.
MATRIX METALLOPROTEINASE ASSAY
Active MMP enzymes were assayed in the conditioned
media and cartilage extracts using the EnzChek
Collagenase/Gelatinase Assay Kit (Molecular Probes,
Eugene, OR). Conditioned media or cartilage extracts were
incubated with DQ-gelatin in reaction buffer (0.5 M Tris-
HCl, 1.5 M NaCl, 50 mM CaCl2, 2 mM Sodium azide, pH
7.6) for 1 h at room temperature. Enzymatic release of
fluorescent signal from DQ-gelatin by either gelatinase or
collagenase was quantified using the Cytofluor 4000 fluor-
escent plate reader (PerSeptive Biosystems, Framingham,
MA). Complete inhibition of gelatinase/collagenase
activity was performed by the addition of 10 mM 1,10-
phenanthroline to the reaction buffer verifying that the
enzyme activity was MMP-dependent. Varying concen-
trations of collagenase from Clostridium histolyticum were
used to establish a standard curve. Tissue gelatinase/
collagenase content was extracted with 1 M guanidine-HCl,
50 mM Tris and 10 mM Calcium chloride,36 dialysed into
reaction buffer and gelatinase/collagenase activity of the
sample was determined as described above. Results were
presented as units of enzyme activity/ml/h relative to the
Clostridium histolyticum standard.
QUANTIFICATION OF PROTEOGLYCAN SYNTHESIS
PG synthesis was quantified by measuring the incorpor-
ation of radioactive sulfur into PGs. Media containing
treatments and 25 Ci of [35S]-sulfate/ml (ICN, Costa
Mesa, CA, U.S.A.) were added to explants and cultured for
24 h. PGs were extracted from explant tissue at 4°C for
72 h with 4 M guanidine hydrochloride including proteinase
inhibitors.37 Proteoglycans were isolated using cetylpyrid-
inium chloride (CPC) precipitation.38,39 Briefly, 100 l of
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chromatography paper and incubated with 0.1% CPC and
0.3 M NaCl. Chromatography paper was dried and
assayed for radioactivity, using a liquid scintillation system.
Results were presented as counts per minute per milligram
of cartilage wet weight (cpm/mg).
STATISTICAL ANALYSIS
Data for indicators of degradation (NO production, PG
release and MMP activity) were analysed using the
repeated measure option of the SAS (1996) statistical
software PROC MIXED.40 No interaction of day was
present so all data were represented as the average
response of the three treatment wells 24 h after treatment
addition. Treatments were compared using the Bonferroni
procedure. Synthesis data were normalized by an inverse
transformation and analysed using PROC GLM.40 Treat-
ments were compared using the least squares difference
procedure. Statistical significance was considered at
P<0.05 unless noted.
Results
Lack of LDH activity indicated that chondrocytes were
viable throughout the culture period. Both LPS (10 g/ml)
and rhIL-1 (50 ng/ml) induced cartilage degradation.
Addition of either LPS or rhIL-1 to the culture system
resulted in a significant increase in NO production, PG
release, and gelatinase/collagenase activity relative to the
control medium. The effect of glucosamine or glucose
control was tested using this degradative system.
EFFECT OF GLUCOSAMINE ON LPS INDUCED CARTILAGE
DEGRADATION
Glucosamine was added at three doses (0.25, 2.5 and
25.0 mg/ml) to the LPS-induced degradative system. When
tested against LPS treatment, glucosamine significantlyinhibited NO production at 2.5 and 25.0 mg/ml (Fig. 1), and
also inhibited PG release at all three doses (Fig. 2). The
highest dose of glucosamine (25.0 mg/ml) also significantly
inhibited PG release compared to the two lower doses
(0.25 and 2.5 mg/ml) (Fig. 2). Glucosamine (25.0 mg/ml)
also significantly inhibited tissue PG synthesis compared to
all other treatments (Fig. 3). At the same glucosamine
dose, tissue PG content was significantly higher (Fig. 4). All
doses of glucosamine significantly decreased gelatinase/
collagenase activity; activity was completely inhibited at
25.0 mg/ml glucosamine using the described method (Fig.
5). MMP activity was not detected in tissue extracts.
Glucose, a sugar moiety control, was added at three
doses (0.21, 2.1 and 21.0 mg/ml) to the LPS induced
degradative system. Glucose did not significantly inhibit
LPS induced NO production (Fig. 1) or PG release (Fig. 2)
at any dose. In addition, glucose did not alter PG synthesis
when compared to FBS (Fig. 3).
EFFECT OF GLUCOSAMINE ON RHIL-1 INDUCED CARTILAGE
DEGRADATION
Glucosamine was added at three doses (0.25, 2.5 and
25.0 mg/ml) to the rhIL-1 induced degradative system.
Glucosamine significantly inhibited NO production at 2.5
and 25 mg/ml when compared to rhIL-1; the low dose
(0.25 mg/ml) did not influence NO production (Fig. 6).
Glucosamine also inhibited PG release at 25.0 mg/ml when
compared to rhIL-1 and the two lower doses did not inhibit
PG release (Fig. 7).
Discussion
These data provide biochemical evidence supporting the
purported chondroprotective properties of glucosamine and
also suggest disease-modifying characteristics of the com-
pound. A chondroprotective agent can be defined as a
substance that increases chondrocyte anabolic activity
while simultaneously suppressing the effect of mediatorsFig. 1. Mean (±SD) nitric oxide production released into the conditioned media 24 h after LPS induced degradation treated with glucose or
glucosamine. *Indicates statistical significance at P≤0.05 compared to LPS and 0.25 mg/ml glucosamine (GLCN). FBS=fetal bovine serum;
LPS=lipopolysaccharide.
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degradation.29 Up-regulated proteolytic degradation of car-
tilage matrix is generally considered a hallmark of OA. A
disease-modifying drug such as glucosamine could reduce
degradation either by inhibiting proteinases or by inhibiting
the activity of mediators such as IL-1. Using indicators of
chondrocyte metabolism (NO production, PG release, PG
synthesis and MMP activity), we have shown that glu-
cosamine (25 mg/ml) inhibits in vitro cartilage degradation
induced by either LPS or the cytokine IL-1. We feel confi-
dent that these responses were due to glucosamine and
were not an artefact of high sugar moieties in the media.
Compared to the LPS treatment, glucose treatment at any
dose did not decrease NO production, PG release, MMP
activity or PG synthesis, indicating the importance of the
amine group in glucosamine.Several explanations may account for the poorly under-
stood action of glucosamine. One mechanism by which
glucosamine may prevent cartilage matrix degradation is
inhibition of NO production. Nitric oxide may be an import-
ant regulatory molecule in the cartilage matrix degradation
cascade, by mediating some of the inhibitory effects of
cytokines on matrix synthesis. The presence of increased
NO levels in the synovial fluid of diseased joints suggests
that NO is involved in articular cartilage degradation. In
addition, NO is up-regulated in human OA cartilage.35 This
increased NO level has been proposed to regulate matrix
degradation by inducing chondrocyte apoptosis,35 inhibit-
ing cell proliferation,41 and activating MMPs.22 In our
system, cartilage degradation induced by either LPS or
rhIL-1 resulted in increased NO production and MMP
activity, both inhibited by glucosamine. NO production mayFig. 2. Mean (±SD) proteoglycan production released into the conditioned media 24 h after LPS induced degradation treated with glucose
or glucosamine. *Indicates statistical significance at P≤0.05 compared to LPS. **Indicates statistical significance at P≤0.05 compared to
other doses of glucosamine (GLCN). FBS=fetal bovine serum; LPS=lipopolysaccharide.Fig. 3. Mean (±SD) tissue proteoglycan synthesis as indicated by counts per min/mg tissue (wet weight) 24 h after LPS induced degradation
treated with glucosamine. *Indicates statistical significance at P≤0.001. FBS=fetal bovine serum; LPS=lipopolysaccharide.
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including regulation of the production or activity of NO
synthase. Alternatively, supplemental glucosamine may
simply quench increased NO or act as an antioxidant and
prevent MMP degradation of the cartilage matrix. The latter
explanation is similar to that reported by Homandberg et al.
(1997), who found that the antioxidant N-acetylcysteine
suppressed IL-1 mediated damage to articular cartilage
and promoted PG repair in vitro.
A second mechanism by which glucosamine may affect
the onset or progression of OA is through the direct
inhibition of MMPs. MMPs are implicated in the OA process
as the main family of enzymes responsible for cartilage
matrix degradation. The importance of MMPs in OA is
evidenced by their elevated activity in OA cartilage. We
have shown that glucosamine is a potent inhibitor of LPS
and rhIL-1 induced gelatinase/collagenase activity at all
doses (0.25, 2.5 and 25.0 mg/ml) tested. The mechanism
remains unclear, but inhibition of expression, synthesis or
activity of MMPs are all possible. Sandy et al. (1998)30
have shown that glucosamine, like mannosamine, is aneffective inhibitor of aggrecanase. Both are effective inhibi-
tors of glycosylphosphatidylinositol anchor synthesis and
the authors suggest that the aggrecanase catabolic unit
may possess a glycosylphosphatidylinositol-linked compo-
nent responsive to glucosamine. Tetracyclines, by interfer-
ing with MMP ability to bind divalent cations, have also
been shown to beneficially affect cartilage and bone loss by
inhibiting MMP activity.42 These drugs may also reduce the
production of MMPs by inhibiting NO synthase.43
Alteration of chondrocyte metabolism by glucosamine
was also evidenced by changes in PG metabolism. Glu-
cosamine inhibited both PG degradation and synthesis. At
first, the reduced rate of PG synthesis may appear detri-
mental to the matrix of articular cartilage. However, we
observed slightly higher tissue PG content at the highest
dose of glucosamine compared to all other treatments.
These data indicated that, although synthesis was
decreased, turnover was also decreased, indicating that
glucosamine may act by preserving the extracellular
matrix. PG synthesis might not have been stimulated
because growth factors such as IGF-1 and FGF wereFig. 4. Mean (±SD) proteoglycan content of tissue remaining upon completion of culture period. Tissue samples were papain digested prior
to quantification of proteoglycans. *Indicates statistical significance at P≤0.05 compared to other treatments. GLCN=glucosamine;
FBS=fetal bovine serum; LPS=lipopolysaccharide.Fig. 5. Mean (±SD) gelatinase/collagenase activity released into the conditioned media 24 h after LPS induced degradation treated with
glucosamine. *Indicates statistical significance at P≤0.05 compared to LPS. **Indicates statistical significance at P≤0.001 compared to other
doses of glucosamine (GLCN).
Osteoarthritis and Cartilage Vol. 8 No. 4 263not proteolytically released from the surrounding extra-
cellular matrix. Thus, if PG degradation is not occurring, PG
synthesis is not up-regulated. Most in vitro studies in
which glucosamine increased PG synthesis used OA carti-
lage. In our study, however, we used normal cartilage,
which may explain the disparity between our results and
others.
Finally, in damaged cartilage, glucosamine production
by chondrocytes may be limited and supplementation
of high levels of glucosamine may restore normal
metabolism. Some have suggested that in OA joints the
demand for ‘building block’ molecules might exceed the
tissues’ ability to produce them.44 Providing glucosamine
exogenously could bypass rate-limiting steps in the syn-
thesis of molecules that inhibit degradation or restore
normal metabolism. To date, this hypothesis has not been
tested.
Although compounds other than glucosamine can
inhibit cartilage degradation, most are not practical for
preventing or treating OA. For example, N-acetylcysteine
and DMSO were shown by Homandberg et al. (1997)34 to
inhibit cartilage degradation. However, if taken orally
these compounds would be toxic. Glucosamine pos-
sesses many qualities that make it an acceptabledisease-modifying or chondroprotective agent. These
qualities include wide availability, relatively low cost,
absence of known side-effects, high oral absorption rate
(>87% in dogs and rats) and ready transfer into carti-
lage.45 Although the most effective dose tested in this
study (25 mg/ml) may be pharmacological, the actual
effective dose in vivo may be significantly less due to
improved fluid flow through the cartilage. Furthermore,
glucosamine could accumulate in articular cartilage over
time with chronic oral administration. Because it is difficult
to study cartilage in vivo, biochemical evidence support-
ing the action of glucosamine is limited. Our in vitro data
substantiate anecdotal in vivo observations. Further
research to elucidate the mechanism through which glu-
cosamine may exert chondroprotective properties in
articular cartilage is under investigation.
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Appendix
LIST OF ABBREVIATIONS
OA: Osteoarthritis
MMP: Matrix metalloproteinase
rhIL-1: Recombinant human interleukin-1
IL-1: Interleukin-1
LPS: Lipopolysaccharide
PG: Proteoglycan
GLCN: Glucosamine
NO: Nitric oxide
FBS: Fetal bovine serum
